Sellas Life Sciences
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +418.8% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 28.3% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Performance
Key statistics
Price & volume
- Prev close
- 14.86
- Open
- 14.98
- Day range
- 13.39 - 15.19
- Avg price
- 13.92
- Volume
- 15.48M
- Turnover
- 215.56M
- Turnover ratei
- 7.62%
- Volume ratioi
- 0.36
- Amplitudei
- 12.15%
- 52-week rangei
- 1.39 - 24.89
Valuation
- P/Ei
- -54.64
- P/E (TTM)i
- -68.30
- P/Bi
- 21.11
- EPSi
- -0.25
- Book value / shi
- 0.65
- Net profit
- -50.96M
- Net assets
- 131.90M
Share structure
- Market cap
- 2.78B
- Float capi
- 2.77B
- Shares out
- 203.86M
- Float sharesi
- 203.06M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
45.1% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-31.41M net over the window
Short interest
- Shares short
- 57.13M
- % of floati
- 28.29%
- Days to coveri
- 6.70
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Sellas Life Sciences (SLS)?
Sellas Life Sciences last traded at 13.66. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Sellas Life Sciences's market cap?
About 2.78B.
What is the P/E ratio of Sellas Life Sciences?
The trailing twelve-month P/E is -68.30. The Valuation tab shows it against the stock's own five-year range.
Does Sellas Life Sciences pay a dividend?
Sellas Life Sciences does not currently pay a regular dividend.
Is Sellas Life Sciences a buy according to analysts?
The consensus of 1 analysts is a Buy rating, with an average 12-month price target of 30.00, which implies 119.6% upside from the current price. This is not investment advice.
What is Sellas Life Sciences's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Sellas Life Sciences a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:58:45 · For reference only, not investment advice and not tailored to your situation.
Sellas Life Sciences discussion 0 comments